SSKN
STRATA Skin Sciences·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 1
High Gross Profit Margin
EPS Beats Expectation
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About SSKN
Strata Skin Sciences, Inc.
A company that developing a non-invasive, point-of-care system to assist in the detection of early melanoma
Healthcare Equipment and Supplies
--
10/31/2005
NASDAQ Stock Exchange
106
12-31
Common stock
5 Walnut Grove Drive, Suite 140 Horsham, Pennsylvania 19044
--
STRATA Skin Sciences, Inc., commenced operations as a New York corporation in December 1989 and was re-incorporated as a Delaware corporation in September 1997. The company is a dermatological medical technology company that develops, commercializes and markets innovative products for the treatment of skin diseases. The company's products include XTRAC and now Pharos excimer lasers and VTRAC light systems for the treatment of psoriasis, vitiligo and various skin conditions. The company's products also include the TheraClear Acne Treatment System for the treatment of mild to moderate inflammatory, acne and pustular acne.
Earnings Call
Company Financials
EPS
SSKN has released its 2025 Q3 earnings. EPS was reported at -0.36, versus the expected -0.24, missing expectations. The chart below visualizes how SSKN has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
SSKN has released its 2025 Q3 earnings report, with revenue of 6.93M, reflecting a YoY change of -21.23%, and net profit of -1.62M, showing a YoY change of 21.79%. The Sankey diagram below clearly presents SSKN's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available

